Amneal Pharmaceuticals Total Assets Growth & History (AMRX)
Amneal Pharmaceuticals's total assets was $3.68B for fiscal 2025.
View full Amneal Pharmaceuticals company overviewAmneal Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.68B | $176.8M | +5.05% |
| 2024 | 2024-12-31 | $3.50B | $28.9M | +0.83% |
| 2023 | 2023-12-31 | $3.47B | −$326.8M | −8.60% |
| 2022 | 2022-12-31 | $3.80B | −$140.3M | −3.56% |
| 2021 | 2021-12-31 | $3.94B | −$66.4M | −1.66% |
| 2020 | 2020-12-31 | $4.01B | $340.1M | +9.28% |
| 2019 | 2019-12-31 | $3.67B | −$686.8M | −15.78% |
| 2018 | 2018-12-31 | $4.35B | $3.01B | +224.37% |
| 2017 | 2017-12-31 | $1.34B | — | — |
Amneal Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.78B | $353.6M | +10.33% |
| Q1 2026 | 2026-03-31 | $3.54B | $175.0M | +5.20% |
| Q4 2025 | 2025-12-31 | $3.68B | $176.8M | +5.05% |
| Q3 2025 | 2025-09-30 | $3.60B | $138.9M | +4.01% |
| Q2 2025 | 2025-06-30 | $3.42B | −$87.1M | −2.48% |
| Q1 2025 | 2025-03-31 | $3.37B | −$91.1M | −2.64% |
| Q4 2024 | 2024-12-31 | $3.50B | $28.9M | +0.83% |
| Q3 2024 | 2024-09-30 | $3.46B | −$226.1M | −6.13% |
| Q2 2024 | 2024-06-30 | $3.51B | −$191.0M | −5.16% |
| Q1 2024 | 2024-03-31 | $3.46B | −$170.2M | −4.69% |
| Q4 2023 | 2023-12-31 | $3.47B | −$326.8M | −8.60% |
| Q3 2023 | 2023-09-30 | $3.69B | −$187.0M | −4.83% |
| Q2 2023 | 2023-06-30 | $3.70B | −$340.5M | −8.43% |
| Q1 2023 | 2023-03-31 | $3.63B | −$262.4M | −6.75% |
| Q4 2022 | 2022-12-31 | $3.80B | −$140.3M | −3.56% |
| Q3 2022 | 2022-09-30 | $3.87B | −$100.4M | −2.53% |
| Q2 2022 | 2022-06-30 | $4.04B | $18.4M | +0.46% |
| Q1 2022 | 2022-03-31 | $3.89B | −$71.1M | −1.80% |
| Q4 2021 | 2021-12-31 | $3.94B | −$66.4M | −1.66% |
| Q3 2021 | 2021-09-30 | $3.97B | −$63.1M | −1.56% |
| Q2 2021 | 2021-06-30 | $4.02B | −$33.7M | −0.83% |
| Q1 2021 | 2021-03-31 | $3.96B | −$430.7M | −9.81% |
| Q4 2020 | 2020-12-31 | $4.01B | $340.1M | +9.28% |
| Q3 2020 | 2020-09-30 | $4.04B | $333.6M | +9.01% |
| Q2 2020 | 2020-06-30 | $4.06B | −$205.4M | −4.82% |
| Q1 2020 | 2020-03-31 | $4.39B | $6.2M | +0.14% |
| Q4 2019 | 2019-12-31 | $3.67B | −$686.8M | −15.78% |
| Q3 2019 | 2019-09-30 | $3.70B | −$878.1M | −19.16% |
| Q2 2019 | 2019-06-30 | $4.26B | −$282.4M | −6.22% |
| Q1 2019 | 2019-03-31 | $4.38B | — | — |
| Q4 2018 | 2018-12-31 | $4.35B | $3.01B | +224.37% |
| Q3 2018 | 2018-09-30 | $4.58B | — | — |
| Q2 2018 | 2018-06-30 | $4.54B | — | — |
| Q4 2017 | 2017-12-31 | $1.34B | — | — |
Amneal Pharmaceuticals total assets trends
Over the last five fiscal years, Amneal Pharmaceuticals's total assets decreased from $4.01B to $3.68B, a change of −$327.8M. The latest reported quarter, Q2 2026, shows $3.78B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amneal Pharmaceuticals source filings ↗